
About HiiMS
HiiMS is a publicly listed company based in Chandigarh (India). Integrated Ayurvedic and medical services for disease management in India. The company has 3,550 employees. Its Indian entity Jeena Sikho Lifecare Limited reported revenue of ₹810 Cr. HiiMS offers products and services including Ayurvedic Treatments and Consultations. Its focus areas include Wellness, Alternative Therapies, Ayurveda and Medical Services.
Company details
HiiMS is known for delivering integrated healthcare services that combine Ayurveda with modern practices across India. A network of over 55 hospitals and 70 clinics is utilized to treat conditions like kidney disease, diabetes, and cancer through natural therapies and patient education. Emphasis is placed on holistic approaches, including diet, yoga, and lifestyle modifications, to promote self-reliance in health. These services are accessed by thousands of patients annually, focusing on reversal of chronic diseases without side effects.
- Headquarters Chandigarh, India
- Employees 3,550
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hiims.in
- Social Facebook Instagram YouTube
- Legal Name Jeena Sikho Life Care Limited
- Date of Incorporation 29 May, 2017
- Jurisdiction Zirakpur, Punjab, India
- Market Cap₹3,729 Cr
JSLL · NSE
- Share Price₹296.35
-1.20% today
- Revenue₹801 Cr
FY 2025-26
- EBITDA₹349 Cr
Margin 43.6%
- Net Profit₹222 Cr
FY 2025-26
- P/E (TTM)18.0x
P/B 7.5x
- ROE61.3%
ROCE 63.7%
- Debt / Equity0.34
Interest cover 4.6x
- Employee Count3,550
Associated legal entities of HiiMS
HiiMS operates through Jeena Sikho Lifecare Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Jeena Sikho Lifecare Limited Listed CIN L52601PB2017PLC046545 | Active | 29 May 2017 | Zirakpur, Punjab | ₹810 Cr | 1,541 | 12 | View details |
Products & Services of HiiMS
HiiMS offers a comprehensive portfolio of products and services, including Ayurvedic Treatments and Consultations.
Ayurvedic treatments are provided for various diseases using natural therapies and integrated methods
Consultations are offered through OPD, virtual platforms, and home services to support patient health management
Apps and channels of HiiMS
its YouTube channel HIIMS has 1.12M subscribers and 30 videos.
Videos from HiiMS
The most watched videos on HiiMS's YouTube channel, HIIMS (1.12M subscribers). Click a video to play it here.
More on HIIMS.
Board of directors of Jeena Sikho Lifecare Limited (HiiMS)
Jeena Sikho Lifecare Limited is the primary company behind HiiMS. The board of Jeena Sikho Lifecare Limited currently have 10 directors; the longest-serving is Shreya Grover, appointed in 2021. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shreya Grover DIN 09199495 | Whole-time director | 12 Jun 2021 | 5 yrs 5 mo | Jeena Sikho Lifecare Limited |
| Karan Vir Bindra DIN 09283623 | Director | 25 Aug 2021 | 5 yrs 2 mo | Jeena Sikho Lifecare Limited |
| Manish Grover DIN 07557886 | Managing Director | 25 Aug 2021 | 5 yrs 2 mo | Jeena Sikho Lifecare Limited |
| Bhavna Grover DIN 07557913 | Whole-time director | 25 Aug 2021 | 5 yrs 2 mo | Jeena Sikho Lifecare Limited |
| Chandan Kumar Kaushal DIN 10515819 | Director | 29 Apr 2024 | 2 yrs 6 mo | Jeena Sikho Lifecare Limited |
| Priyanka Bansal DIN 09051665 | Director | 21 Apr 2025 | 1 yr 6 mo | Jeena Sikho Lifecare Limited |
| Ankush Kaushal DIN 03308862 | Whole-time director | 15 Jul 2026 | 4 mo | Jeena Sikho Lifecare Limited |
| Ajay Sharma DIN 07671350 | Director | 15 Jul 2026 | 4 mo | Jeena Sikho Lifecare Limited |
| Sapna Singh DIN 11812894 | Director | 15 Jul 2026 | 4 mo | Jeena Sikho Lifecare Limited |
| Ish Sharma DIN 11815526 | Whole-time director | 15 Jul 2026 | 4 mo | Jeena Sikho Lifecare Limited |
IPO & Listings of HiiMS
HiiMS is a publicly listed company on the NSE with ticker symbol JSLL in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: JSLL
- Listed entityJeena Sikho Lifecare Limited
- Exchange sectorPharmaceuticals
Financials of HiiMS
Exchange-reported figures of Jeena Sikho Lifecare Limited, the listed company behind HiiMS (NSE: JSLL).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Income statement | |||
| Revenue | 801 | 205 | 147 |
| Revenue growth | - | +39.7% | - |
| EBITDA | 349 | 45.85 | 18.09 |
| EBITDA margin | +43.6% | +22.4% | +12.3% |
| Profit before tax | 297 | 44.30 | 15.09 |
| Net profit | 222 | 33.39 | 10.65 |
| Net profit margin | +27.7% | +16.3% | +7.3% |
| EPS (₹) | 17.81 | 24.46 | 11.11 |
| Balance sheet | |||
| Total assets | 601 | 127 | 44.00 |
| Net worth | 467 | 126 | 36.51 |
| Total debt | 127 | 0.81 | 7.43 |
| Cash & bank | 109 | 32.39 | 2.59 |
| Net working capital | 172 | 48.59 | 4.26 |
| Cash flow | |||
| Cash from operations | 254 | 14.52 | 16.35 |
| Cash from investing | (202) | (33.10) | (18.49) |
| Cash from financing | (58.68) | 48.00 | (4.51) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 224 | 216 | 222 | 190 | 174 | 139 | 116 |
| Revenue growth (YoY) | +23.9% | +28.8% | +54.8% | +91.6% | +66.4% | +74.2% | - | - |
| Other income | (1.94) | 14.33 | 3.42 | 2.57 | 1.44 | 1.07 | 0.27 | 0.39 |
| EBITDA | 71.99 | 92.06 | 77.92 | 101 | 92.03 | 78.76 | 45.77 | 29.61 |
| EBITDA margin | +30.6% | +41.0% | +36.1% | +45.4% | +48.5% | +45.2% | +32.9% | +25.6% |
| Depreciation | 16.49 | 15.39 | 16.38 | 11.26 | 10.40 | 9.65 | 9.03 | 8.47 |
| Interest | 4.04 | 3.47 | 3.73 | 3.10 | 4.35 | 1.66 | 3.10 | 3.79 |
| Profit before tax | 49.52 | 87.53 | 61.23 | 88.93 | 78.72 | 68.52 | 33.91 | 17.74 |
| Tax | 12.90 | 21.64 | 16.14 | 22.33 | 19.97 | 17.24 | 8.58 | 4.53 |
| Net profit | 36.62 | 65.89 | 45.09 | 66.60 | 58.75 | 51.28 | 25.33 | 13.21 |
| EPS (₹) | 2.94 | 5.29 | 3.62 | 5.35 | 4.72 | 4.12 | 2.04 | 1.06 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 801 | 469 | 324 | 204 | 146 | 136 | 94.42 |
| Revenue growth | +70.8% | +44.6% | +59.1% | +39.2% | +7.8% | +43.8% | - |
| EBITDA | 350 | 125 | 93.01 | 46.32 | 18.16 | 16.96 | 10.55 |
| EBITDA margin | +43.6% | +26.7% | +28.7% | +22.7% | +12.4% | +12.5% | +11.2% |
| Profit before tax | 298 | 122 | 93.92 | 44.52 | 15.16 | 14.21 | 7.73 |
| Net profit | 222 | 88.25 | 67.87 | 33.34 | 10.68 | 10.42 | 5.74 |
| Net profit margin | +27.7% | +18.8% | +20.9% | +16.4% | +7.3% | +7.7% | +6.1% |
| EPS (₹) | 17.85 | 36.50 | 27.84 | 24.43 | 11.15 | 1,015.21 | 572.63 |
| Balance sheet | |||||||
| Total assets | 601 | 377 | 193 | 127 | 44.07 | 36.46 | 26.41 |
| Net worth | 467 | 256 | 192 | 126 | 36.55 | 23.95 | 13.73 |
| Total debt | 127 | 117 | 0.54 | 0.81 | 7.43 | 12.03 | 12.46 |
| Cash & bank | 108 | 22.98 | 62.01 | 32.39 | 2.57 | 8.96 | 1.44 |
| Net working capital | 163 | 90.09 | 114 | 48.59 | 4.83 | 13.70 | 9.46 |
| Cash flow | |||||||
| Cash from operations | 262 | 84.50 | 36.69 | 17.17 | 17.48 | 17.53 | 11.74 |
| Cash from investing | (211) | (64.38) | (18.05) | (57.23) | (19.64) | (8.47) | (5.97) |
| Cash from financing | (58.73) | (22.45) | (3.44) | 48.00 | (4.51) | (1.53) | (5.05) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 224 | 216 | 222 | 190 | 174 | 139 | 116 |
| Revenue growth (YoY) | +23.9% | +28.8% | +54.8% | +91.6% | +66.4% | +74.2% | - | - |
| Other income | (2.31) | 14.02 | 3.58 | 2.57 | 1.44 | 1.07 | 0.27 | 0.39 |
| Total expenses | 163 | 132 | 138 | 121 | 97.78 | 95.50 | 93.48 | 86.08 |
| EBITDA | 72.03 | 92.12 | 77.98 | 101 | 92.07 | 78.79 | 45.77 | 29.61 |
| EBITDA margin | +30.6% | +41.1% | +36.2% | +45.5% | +48.5% | +45.2% | +32.9% | +25.6% |
| Depreciation | 16.43 | 15.33 | 16.32 | 11.21 | 10.40 | 9.65 | 9.03 | 8.47 |
| Interest | 4.04 | 3.47 | 3.73 | 3.10 | 4.35 | 1.66 | 3.10 | 3.79 |
| Profit before tax | 49.25 | 87.34 | 61.51 | 89.05 | 78.76 | 68.55 | 33.91 | 17.74 |
| Tax | 12.91 | 21.65 | 16.15 | 22.33 | 19.97 | 17.24 | 8.58 | 4.53 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 224 | 216 | 222 | 190 | 174 | 139 | 116 |
| Revenue growth (YoY) | +23.9% | +28.8% | +54.8% | +91.6% | +66.4% | +74.2% | - | - |
| Other income | (1.94) | 14.33 | 3.42 | 2.57 | 1.44 | 1.07 | 0.27 | 0.39 |
| EBITDA | 71.99 | 92.06 | 77.92 | 101 | 92.03 | 78.76 | 45.77 | 29.61 |
| EBITDA margin | +30.6% | +41.0% | +36.1% | +45.4% | +48.5% | +45.2% | +32.9% | +25.6% |
| Depreciation | 16.49 | 15.39 | 16.38 | 11.26 | 10.40 | 9.65 | 9.03 | 8.47 |
| Interest | 4.04 | 3.47 | 3.73 | 3.10 | 4.35 | 1.66 | 3.10 | 3.79 |
| Profit before tax | 49.52 | 87.53 | 61.23 | 88.93 | 78.72 | 68.52 | 33.91 | 17.74 |
| Tax | 12.90 | 21.64 | 16.14 | 22.33 | 19.97 | 17.24 | 8.58 | 4.53 |
| Net profit | 36.62 | 65.89 | 45.09 | 66.60 | 58.75 | 51.28 | 25.33 | 13.21 |
| EPS (₹) | 2.94 | 5.29 | 3.62 | 5.35 | 4.72 | 4.12 | 2.04 | 1.06 |
| Particulars | FY 2025-26 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Revenue | 801 | 205 | 147 |
| Revenue growth | - | +39.7% | - |
| Other income | 8.50 | 2.60 | 1.49 |
| Total expenses | 452 | 159 | 128 |
| Employee cost | 0.00 | 44.05 | 33.80 |
| EBITDA | 349 | 45.85 | 18.09 |
| EBITDA margin | +43.6% | +22.4% | +12.3% |
| Depreciation | 47.69 | 3.20 | 3.31 |
| Interest | 12.83 | 0.95 | 1.18 |
| Profit before tax | 297 | 44.30 | 15.09 |
| Tax | 75.69 | 10.77 | 3.89 |
| Net profit | 222 | 33.39 | 10.65 |
| Net profit margin | +27.7% | +16.3% | +7.3% |
| EPS (₹) | 17.81 | 24.46 | 11.11 |
| Particulars | FY 2025-26 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 24.86 | 13.81 | 10.11 |
| Reserves & surplus | 442 | 112 | 26.40 |
| Shareholders' funds (net worth) | 467 | 126 | 36.51 |
| Minority interest | (0.13) | 0.00 | (0.03) |
| Secured loans | 0.43 | 0.81 | 1.08 |
| Unsecured loans | 127 | 0.00 | 6.35 |
| Total debt | 127 | 0.81 | 7.43 |
| Total liabilities | 601 | 127 | 44.00 |
| Assets | |||
| Gross block | 384 | 70.76 | 36.84 |
| Net block | 293 | 59.74 | 28.59 |
| Capital work in progress | 2.86 | 1.13 | 5.04 |
| Investments | 110 | 4.55 | 0.00 |
| Inventories | 20.22 | 4.10 | 6.36 |
| Sundry debtors | 69.93 | 22.07 | 9.04 |
| Cash & bank balances | 109 | 32.39 | 2.59 |
| Loans & advances | 46.78 | 14.36 | 3.53 |
| Total current assets | 246 | 72.92 | 21.52 |
| Total current liabilities | 73.43 | 24.33 | 17.26 |
| Net working capital | 172 | 48.59 | 4.26 |
| Total assets | 601 | 127 | 44.00 |
| Particulars | FY 2025-26 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Opening cash | 22.98 | 2.19 | 8.84 |
| Net cash from operating activities | 254 | 14.52 | 16.35 |
| Net cash from investing activities | (202) | (33.10) | (18.49) |
| Net cash from financing activities | (58.68) | 48.00 | (4.51) |
| Net change in cash | (6.61) | 29.42 | (6.65) |
| Closing cash | 109 | 32.39 | 2.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | - | +129.1% | +39.7% | - |
| EBITDA growth | - | +206.7% | +153.5% | - |
| PBT growth | +176.5% | +142.8% | +193.6% | +9997.0% |
| Net income growth | - | +132.4% | +213.5% | - |
| Revenue CAGR (3Y) | +76.2% | - | - | - |
| EBITDA CAGR (3Y) | +168.6% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +27.7% | +17.0% | +16.4% | +7.6% |
| Return on capital employed | +63.7% | +31.4% | +53.0% | +37.0% |
| Return on net worth | +61.3% | +31.2% | +41.3% | +30.7% |
| Debt / equity | 0.34 | 0.46 | 0.05 | 0.20 |
| Long-term debt / equity | 0.25 | 0.33 | 0.01 | 0.02 |
| Interest cover | 4.58 | 9.55 | 2.23 | 7.98 |
| Efficiency & per share | ||||
| Fixed asset turnover | 2.35 | 1.58 | 3.81 | 3.98 |
| Inventory turnover | 50.45 | 40.61 | 39.15 | 23.04 |
| Debtors turnover | 10.35 | 5.52 | 13.16 | 16.21 |
| EPS (₹) | 17.84 | 32.16 | 24.46 | 11.11 |
| Dividend per share (₹) | 4.50 | 5.47 | 2.00 | 0.00 |
| Book value per share (₹) | 37.58 | 103.11 | 91.09 | 36.11 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 224 | 216 | 222 | 190 | 174 | 139 | 116 |
| Revenue growth (YoY) | +23.9% | +28.8% | +54.8% | +91.6% | +66.4% | +74.2% | - | - |
| Other income | (2.31) | 14.02 | 3.58 | 2.57 | 1.44 | 1.07 | 0.27 | 0.39 |
| Total expenses | 163 | 132 | 138 | 121 | 97.78 | 95.50 | 93.48 | 86.08 |
| EBITDA | 72.03 | 92.12 | 77.98 | 101 | 92.07 | 78.79 | 45.77 | 29.61 |
| EBITDA margin | +30.6% | +41.1% | +36.2% | +45.5% | +48.5% | +45.2% | +32.9% | +25.6% |
| Depreciation | 16.43 | 15.33 | 16.32 | 11.21 | 10.40 | 9.65 | 9.03 | 8.47 |
| Interest | 4.04 | 3.47 | 3.73 | 3.10 | 4.35 | 1.66 | 3.10 | 3.79 |
| Profit before tax | 49.25 | 87.34 | 61.51 | 89.05 | 78.76 | 68.55 | 33.91 | 17.74 |
| Tax | 12.91 | 21.65 | 16.15 | 22.33 | 19.97 | 17.24 | 8.58 | 4.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 801 | 469 | 324 | 204 | 146 | 136 | 94.42 |
| Revenue growth | +70.8% | +44.6% | +59.1% | +39.2% | +7.8% | +43.8% | - |
| Other income | 8.66 | 6.41 | 6.44 | 2.28 | 1.49 | 1.07 | 0.76 |
| Total expenses | 452 | 344 | 231 | 158 | 128 | 119 | 83.87 |
| Employee cost | 0.00 | 100 | 65.91 | 43.44 | 33.75 | 30.38 | 21.65 |
| EBITDA | 350 | 125 | 93.01 | 46.32 | 18.16 | 16.96 | 10.55 |
| EBITDA margin | +43.6% | +26.7% | +28.7% | +22.7% | +12.4% | +12.5% | +11.2% |
| Depreciation | 47.58 | 8.71 | 5.10 | 3.13 | 3.31 | 2.46 | 1.94 |
| Interest | 12.83 | 0.97 | 0.43 | 0.95 | 1.18 | 1.36 | 1.64 |
| Profit before tax | 298 | 122 | 93.92 | 44.52 | 15.16 | 14.21 | 7.73 |
| Tax | 75.70 | 31.34 | 24.71 | 10.78 | 3.89 | 3.89 | 1.99 |
| Net profit | 222 | 88.25 | 67.87 | 33.34 | 10.68 | 10.42 | 5.74 |
| Net profit margin | +27.7% | +18.8% | +20.9% | +16.4% | +7.3% | +7.7% | +6.1% |
| EPS (₹) | 17.85 | 36.50 | 27.84 | 24.43 | 11.15 | 1,015.21 | 572.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.86 | 24.86 | 24.86 | 13.81 | 10.11 | 0.10 | 0.10 |
| Reserves & surplus | 443 | 231 | 167 | 112 | 26.44 | 23.85 | 13.63 |
| Shareholders' funds (net worth) | 467 | 256 | 192 | 126 | 36.55 | 23.95 | 13.73 |
| Secured loans | 0.43 | 0.74 | 0.54 | 0.81 | 1.08 | 0.23 | 0.66 |
| Unsecured loans | 127 | 116 | 0.00 | 0.00 | 6.35 | 11.80 | 11.80 |
| Total debt | 127 | 117 | 0.54 | 0.81 | 7.43 | 12.03 | 12.46 |
| Total liabilities | 601 | 377 | 193 | 127 | 44.07 | 36.46 | 26.41 |
| Assets | |||||||
| Gross block | 383 | 298 | 82.38 | 70.76 | 36.59 | 28.33 | 19.98 |
| Net block | 292 | 253 | 66.85 | 59.74 | 28.34 | 22.68 | 16.66 |
| Capital work in progress | 2.71 | 13.48 | 3.94 | 1.13 | 5.04 | 0.00 | 0.00 |
| Investments | 110 | 3.56 | 4.14 | 4.55 | 0.01 | 0.00 | 0.00 |
| Inventories | 20.17 | 11.55 | 7.19 | 4.10 | 5.76 | 9.28 | 10.56 |
| Sundry debtors | 69.93 | 84.96 | 41.19 | 22.07 | 8.97 | 3.24 | 4.38 |
| Cash & bank balances | 108 | 22.98 | 62.01 | 32.39 | 2.57 | 8.96 | 1.44 |
| Loans & advances | 37.50 | 12.58 | 30.46 | 14.36 | 4.74 | 4.61 | 4.54 |
| Total current assets | 235 | 132 | 141 | 72.92 | 22.04 | 26.09 | 20.92 |
| Total current liabilities | 71.89 | 41.98 | 27.19 | 24.33 | 17.21 | 12.39 | 11.46 |
| Net working capital | 163 | 90.09 | 114 | 48.59 | 4.83 | 13.70 | 9.46 |
| Total assets | 601 | 377 | 193 | 127 | 44.07 | 36.46 | 26.41 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 22.98 | 25.31 | 10.12 | 2.17 | 8.84 | 1.44 | 0.71 |
| Net cash from operating activities | 262 | 84.50 | 36.69 | 17.17 | 17.48 | 17.53 | 11.74 |
| Net cash from investing activities | (211) | (64.38) | (18.05) | (57.23) | (19.64) | (8.47) | (5.97) |
| Net cash from financing activities | (58.73) | (22.45) | (3.44) | 48.00 | (4.51) | (1.53) | (5.05) |
| Net change in cash | (7.82) | (2.34) | 15.20 | 7.94 | (6.67) | 7.53 | 0.73 |
| Closing cash | 108 | 22.98 | 62.01 | 32.39 | 2.57 | 8.96 | 1.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +70.8% | +44.6% | +59.1% | +39.2% | +7.8% | +43.8% | - |
| EBITDA growth | +179.0% | +34.8% | +100.8% | +155.1% | +7.1% | +60.8% | - |
| PBT growth | +176.9% | +14.5% | +111.0% | +193.7% | +6.7% | +83.8% | -7.1% |
| Net income growth | +151.8% | +30.0% | +103.6% | +212.2% | +2.5% | +81.5% | - |
| Revenue CAGR (3Y) | +57.8% | +47.4% | +33.7% | +29.3% | +11.4% | - | - |
| EBITDA CAGR (3Y) | +96.4% | +97.8% | +76.4% | +63.8% | +19.6% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.7% | +17.0% | +21.3% | +16.6% | +7.7% | +7.6% | +6.1% |
| Return on capital employed | +63.7% | +41.5% | +59.0% | +53.3% | +40.6% | +49.4% | +37.4% |
| Return on net worth | +61.4% | +35.6% | +43.5% | +41.6% | +37.3% | +54.6% | +52.7% |
| Debt / equity | 0.34 | 0.26 | 0.00 | 0.05 | 0.32 | 0.65 | 1.29 |
| Long-term debt / equity | 0.25 | 0.19 | 0.00 | 0.01 | 0.02 | 0.02 | 0.05 |
| Interest cover | 4.58 | 9.55 | 0.49 | 2.20 | 7.95 | 9.38 | 19.05 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.35 | 2.47 | 4.24 | 3.80 | 4.51 | 5.62 | 5.55 |
| Inventory turnover | 50.53 | 50.06 | 57.47 | 41.36 | 19.47 | 13.69 | 8.13 |
| Debtors turnover | 10.35 | 7.44 | 10.26 | 13.14 | 23.99 | 35.65 | 22.01 |
| EPS (₹) | 17.87 | 32.16 | 27.84 | 24.43 | 11.15 | 1,015.21 | 572.63 |
| Dividend per share (₹) | 4.50 | 5.47 | 4.80 | 2.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 37.60 | 103.11 | 77.33 | 91.09 | 36.15 | 2,362.31 | 1,372.83 |
Web traffic of HiiMS
Websites that share an audience with HiiMS (hiims.in).
Websites whose visitors overlap most with HiiMS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aryavaidyasala.com | 84% | 339.5K | #115,508 | View details | |
| drvaidyas.com | 83% | 292.3K | #213,781 | View details | |
| kimshospitals.com | 82% | 357.2K | #91,559 | View details | |
| bombayhospitalindore.com | 79% | 12.2K | #1,243,045 | View details | |
| regencyhealthcare.in | 78% | 33.5K | #931,629 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for HiiMS
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Alternative Medicine Products
3 companies that operate in the same segment as HiiMS (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Homeopathic medicine manufacturing and online retail in India. | 1898 | Noida, Uttar Pradesh, India | USD 26.35 M | 1,192 | ||
Operates an online store specializing in ayurvedic and homeopathic medicines. | 2016 | Delhi, Delhi, India | USD 1.25 M | 16 | ||
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness. | 1992 | Faridabad, Haryana, India | USD 10.08 M | 570 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hiims
Complete news archive for HiiMS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HiiMS
HiiMS is headquartered in Chandigarh, India.
HiiMS has 3,550 employees.
The primary company behind HiiMS, Jeena Sikho Lifecare Limited, reported revenue of ₹810 Cr for FY 2026, up 291% year on year.
HiiMS is known for delivering integrated healthcare services that combine Ayurveda with modern practices across India. A network of over 55 hospitals and 70 clinics is utilized to treat conditions like kidney disease, diabetes, and cancer through natural therapies and patient education. Emphasis is placed on holistic approaches, including diet, yoga, and lifestyle modifications, to promote self-reliance in health. These services are accessed by thousands of patients annually, focusing on reversal of chronic diseases without side effects.
HiiMS offers Ayurvedic Treatments and Consultations.
Yes, HiiMS is publicly traded on NSE under the ticker symbol JSLL.
HiiMS operates through Jeena Sikho Lifecare Limited.
The legal entities of HiiMS currently have 12 directors, including Karan Vir Bindra, Manish Grover, Shreya Grover and others.
